U.S. starts review for national Medicare coverage policy for Biogen’s Aduhelm


Article content

The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc’s Alzheimer’s drug, Aduhelm, that was recently approved by the country’s health regulator.

The Centers for Medicare & Medicaid Services expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H) (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)



Source link

Latest

What does FDA approval of Biogen’s Alzheimer’s drug mean for patients?

Article content The U.S. Food and Drug Administration has approved Biogen’s aducanumab, the first drug to target an underlying cause of Alzheimer’s disease....

RTP Global, founders of Cred, ShareChat, Snapdeal, others invest in online truck booking portal for SMEs

Vahak uses an auction marketplace app which allows customers to directly connect with transporters and truck owners and book trucks, trailers, and loads...

Best Mountain Biking T-Shirts For Comfort & Style

If you’re a mountain biker, one of the first things you should invest in is a good set of bike shirts. Some mountain bikers...